Investors Buy High Volume of Call Options on Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics Inc (NASDAQ:ONCE) saw unusually large options trading on Thursday. Stock investors acquired 12,166 call options on the company. This is an increase of 1,270% compared to the average volume of 888 call options.

ONCE has been the topic of a number of research reports. ValuEngine lowered Spark Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Mizuho reaffirmed a “hold” rating and set a $114.50 target price on shares of Spark Therapeutics in a research report on Monday, August 12th. Finally, Zacks Investment Research lowered Spark Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and one has given a buy rating to the company’s stock. Spark Therapeutics presently has an average rating of “Hold” and an average target price of $92.63.

NASDAQ ONCE opened at $108.64 on Friday. The business has a fifty day simple moving average of $100.13 and a 200 day simple moving average of $103.12. Spark Therapeutics has a 12 month low of $34.53 and a 12 month high of $114.20. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.56 and a quick ratio of 5.22.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.58). The company had revenue of $13.50 million during the quarter, compared to analysts’ expectations of $27.71 million. Spark Therapeutics had a negative net margin of 397.68% and a negative return on equity of 48.70%. On average, analysts anticipate that Spark Therapeutics will post -4.97 earnings per share for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Chicago Capital Management LLC raised its position in Spark Therapeutics by 20.0% in the 2nd quarter. Chicago Capital Management LLC now owns 121,000 shares of the biotechnology company’s stock valued at $12,388,000 after buying an additional 20,183 shares during the last quarter. Swiss National Bank raised its stake in shares of Spark Therapeutics by 12.9% in the second quarter. Swiss National Bank now owns 69,900 shares of the biotechnology company’s stock worth $7,156,000 after purchasing an additional 8,000 shares during the last quarter. Gabelli Funds LLC raised its stake in shares of Spark Therapeutics by 5.1% in the second quarter. Gabelli Funds LLC now owns 622,467 shares of the biotechnology company’s stock worth $63,728,000 after purchasing an additional 30,329 shares during the last quarter. EcoR1 Capital LLC raised its stake in shares of Spark Therapeutics by 16.1% in the second quarter. EcoR1 Capital LLC now owns 614,128 shares of the biotechnology company’s stock worth $62,874,000 after purchasing an additional 85,128 shares during the last quarter. Finally, Havens Advisors LLC raised its stake in shares of Spark Therapeutics by 114.8% in the second quarter. Havens Advisors LLC now owns 53,700 shares of the biotechnology company’s stock worth $5,498,000 after purchasing an additional 28,700 shares during the last quarter. 86.41% of the stock is owned by institutional investors and hedge funds.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.

Featured Story: How Does the Quiet Period Work?

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.